Vima banks $100m in Series A to progress Parkinson’s drug

The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.